



Safety and Autoimmune Response to SARS-CoV-2 Vaccination

Guest Editor:

Dr. Minghui Yang

Department of Surgery,
Kaohsiung Medical University
Hospital, Kaohsiung Medical
University, Kaohsiung 807,
Taiwan

Deadline for manuscript
submissions:

closed (20 November 2023)

Message from the Guest Editor

Dear Colleagues,

Coronavirus disease 2019 (COVID-19) is a new global public health crisis affecting the entire world. Following the introduction and wide use of SARS-CoV-2 vaccination, different adverse effects and complications were reported. Although important post-marketing surveillance of vaccines is ongoing, SARS-CoV-2 vaccines are currently still considered highly effective and safe, even with neurological adverse events following immunization (AEFI). These transient symptoms include cerebral venous sinus thrombosis, demyelinating episodes, lymphadenopathy, nausea, cognitive decline, or local influences of swelling, erythema, pain, fever/chills, fatigue, headache, dizziness, muscle weakness, and myalgia/arthralgia.

This Special Issue aims to publish high-quality reviews, regular research papers, communications, and case reports on the safety of the SARS-CoV-2 vaccine in the general population and in special groups, proposals of different schedules and their effects on vaccine safety, security of neurological adverse events following immunization, and other aspects that may be proposed.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com